Astec LifeSciences Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ASTEC.NS | IPL.NS | RALLIS.NS | INSECTICID.NS | ADVANCE.BO | 603599.SS | |
|---|---|---|---|---|---|---|
| Market cap | 12.51B | 13.35B | 37.36B | 15.95B | 8.04B | 9.58B |
| P/E (TTM) | — | 12.4 | 19.0 | 12.7 | 16.7 | 14.2 |
| Forward P/E | 51.0 | 9.8 | 14.5 | 8.1 | — | 9.7 |
| Price/book | 3.7 | 1.3 | 1.7 | 1.3 | 2.3 | 0.9 |
| Dividend yield | — | 0.65% | 1.58% | 0.72% | — | 2.66% |
| 1-year change | −13.66% | −37.17% | −27.36% | −20.35% | −7.36% | −12.98% |
| Today | −1.08% | +0.69% | +1.29% | −1.21% | −4.94% | +1.94% |
The closest companies by business and industry (Agricultural Inputs). Prices may be delayed up to 15 min.
Latest news
All ASTEC.NS news ›Astec LifeSciences Reports ₹37.4 Crore Loss In Q2 FY27 As Total Income Declines By 3%
Astec LifeSciences recorded a consolidated net loss of ₹37.4 crore for the second quarter of fiscal year 2027, an increase from ₹24.4 crore in the previous year. Total income decreased by 3% to ₹72.6 crore. Mumbai: Astec LifeSciences…
Astec LifeSciences Ltd announces Q2FY27, H1FY27 results
26 Oct 2026, 11:32 PM IST Equity Bulls Q2 FY27 Financial Summary Revenue from Enterprise Products stood at ₹57 crore in Q2 FY27, as compared to ₹61 crore in Q2 FY26, primarily led by lower volumes in its key enterprise molecules and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- equitybulls.com1
- freepressjournal.in1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.